O	0	4	Long
O	4	5	-
O	5	9	term
O	10	17	results
O	18	20	of
O	21	34	International
O	35	41	Breast
O	42	48	Cancer
O	49	54	Study
O	55	60	Group
O	61	66	Trial
O	67	71	VIII
O	71	72	:
B-intervention	73	81	adjuvant
I-intervention	82	94	chemotherapy
I-intervention	95	99	plus
I-intervention	100	109	goserelin
O	110	118	compared
O	119	123	with
O	124	130	either
B-control	131	138	therapy
I-control	139	144	alone
O	145	148	for
B-eligibility	149	162	premenopausal
I-eligibility	163	171	patients
I-eligibility	172	176	with
I-eligibility	177	181	node
I-eligibility	181	182	-
I-eligibility	182	190	negative
I-eligibility	191	197	breast
I-eligibility	198	204	cancer
O	204	205	.

O	206	209	The
O	210	223	International
O	224	230	Breast
O	231	237	Cancer
O	238	243	Study
O	244	249	Group
O	250	255	Trial
O	256	260	VIII
O	261	269	compared
O	270	274	long
O	274	275	-
O	275	279	term
O	280	288	efficacy
O	289	291	of
O	292	301	endocrine
O	302	309	therapy
O	310	311	(
O	311	320	goserelin
O	320	321	)
O	321	322	,
O	323	335	chemotherapy
O	336	337	[
O	337	353	cyclophosphamide
O	353	354	,
O	355	367	methotrexate
O	368	371	and
O	372	384	fluorouracil
O	385	386	(
O	386	389	CMF
O	389	390	)
O	390	391	]
O	391	392	,
O	393	396	and
O	397	411	chemoendocrine
O	412	419	therapy
O	420	421	(
O	421	424	CMF
O	425	433	followed
O	434	436	by
O	437	446	goserelin
O	446	447	)
O	448	451	for
O	452	455	pre
O	455	456	/
O	456	470	perimenopausal
O	471	476	women
O	477	481	with
O	482	487	lymph
O	487	488	-
O	488	492	node
O	492	493	-
O	493	501	negative
O	502	508	breast
O	509	515	cancer
O	515	516	.

O	517	521	From
O	522	526	1990
O	527	529	to
O	530	534	1999
O	534	535	,
B-total-participants	536	540	1063
O	541	549	patients
O	550	554	were
O	555	565	randomized
O	566	568	to
O	569	576	receive
O	577	578	(
O	578	579	i
O	579	580	)
O	581	590	goserelin
O	591	594	for
O	595	597	24
O	598	604	months
O	605	606	(
O	606	607	n
O	608	609	=
B-intervention-participants	610	613	346
O	613	614	)
O	614	615	,
O	616	617	(
O	617	619	ii
O	619	620	)
O	621	624	six
O	625	632	courses
O	633	635	of
O	636	637	'
O	637	646	classical
O	646	647	'
O	648	651	CMF
O	652	653	(
O	653	669	cyclophosphamide
O	669	670	,
O	671	683	methotrexate
O	683	684	,
O	685	686	5
O	686	687	-
O	687	699	fluorouracil
O	699	700	)
O	701	713	chemotherapy
O	714	715	(
O	715	716	n
O	717	718	=
B-control-participants	719	722	360
O	722	723	)
O	723	724	,
O	725	727	or
O	728	729	(
O	729	732	iii
O	732	733	)
O	734	737	six
O	738	745	courses
O	746	748	of
O	749	752	CMF
O	753	757	plus
O	758	760	18
O	761	767	months
O	768	777	goserelin
O	778	779	(
O	779	782	CMF
O	782	783	→
O	784	793	goserelin
O	793	794	;
O	795	796	n
O	797	798	=
B-intervention-participants	799	802	357
O	802	803	)
O	803	804	.

O	805	811	Tumors
O	812	816	were
O	817	827	classified
O	828	830	as
O	831	839	estrogen
O	840	848	receptor
O	849	850	(
O	850	852	ER
O	852	853	)
O	854	862	negative
O	863	864	(
O	864	866	19
O	866	867	%
O	867	868	)
O	868	869	,
O	870	872	ER
O	873	881	positive
O	882	883	(
O	883	885	80
O	885	886	%
O	886	887	)
O	887	888	,
O	889	891	or
O	892	894	ER
O	895	902	unknown
O	903	904	(
O	904	905	1
O	905	906	%
O	906	907	)
O	907	908	;
O	909	911	19
O	911	912	%
O	913	915	of
O	916	924	patients
O	925	929	were
O	930	937	younger
O	938	942	than
O	943	945	40
O	945	946	.

O	947	953	Median
O	954	960	follow
O	960	961	-
O	961	963	up
O	964	967	was
O	968	970	12
O	970	971	.
O	971	972	1
O	973	978	years
O	978	979	.

O	980	983	For
O	984	987	the
B-outcome	988	990	ER
I-outcome	990	991	-
I-outcome	991	999	positive
I-outcome	1000	1006	cohort
I-outcome	1006	1007	,
O	1008	1018	sequential
O	1019	1026	therapy
O	1027	1035	provided
O	1036	1037	a
O	1038	1051	statistically
O	1052	1063	significant
O	1064	1071	benefit
O	1072	1074	in
B-outcome	1075	1082	disease
I-outcome	1082	1083	-
I-outcome	1083	1087	free
I-outcome	1088	1096	survival
I-outcome	1097	1098	(
I-outcome	1098	1101	DFS
I-outcome	1101	1102	)
O	1103	1104	(
B-outcome	1104	1106	12
I-outcome	1106	1107	-
I-outcome	1107	1111	year
I-outcome	1112	1115	DFS
O	1116	1117	=
B-iv-bin-percent	1118	1120	77
I-iv-bin-percent	1120	1121	%
O	1121	1122	)
O	1123	1131	compared
O	1132	1136	with
O	1137	1140	CMF
O	1141	1146	alone
O	1147	1148	(
B-cv-bin-percent	1148	1150	69
I-cv-bin-percent	1150	1151	%
O	1151	1152	)
O	1153	1156	and
O	1157	1166	goserelin
O	1167	1172	alone
O	1173	1174	(
B-iv-bin-percent	1174	1176	68
I-iv-bin-percent	1176	1177	%
O	1177	1178	)
O	1179	1180	(
O	1180	1181	P
O	1182	1183	=
O	1184	1185	0
O	1185	1186	.
O	1186	1188	04
O	1189	1192	for
O	1193	1197	each
O	1198	1208	comparison
O	1208	1209	)
O	1209	1210	,
O	1211	1214	due
O	1215	1222	largely
O	1223	1225	to
O	1226	1229	the
O	1230	1236	effect
O	1237	1239	in
O	1240	1247	younger
O	1248	1256	patients
O	1256	1257	.

O	1258	1266	Patients
O	1267	1271	with
B-outcome	1272	1274	ER
I-outcome	1274	1275	-
I-outcome	1275	1283	negative
I-outcome	1284	1290	tumors
O	1291	1296	whose
O	1297	1306	treatment
O	1307	1315	included
O	1316	1319	CMF
O	1320	1323	had
O	1324	1331	similar
B-outcome	1332	1335	DFS
O	1336	1337	(
B-outcome	1337	1339	12
I-outcome	1339	1340	-
I-outcome	1340	1344	year
I-outcome	1345	1348	DFS
O	1349	1352	CMF
O	1353	1354	=
B-cv-bin-percent	1355	1357	67
I-cv-bin-percent	1357	1358	%
O	1358	1359	;
O	1360	1362	12
O	1362	1363	-
O	1363	1367	year
O	1368	1371	DFS
O	1372	1375	CMF
O	1375	1376	→
O	1377	1386	goserelin
O	1387	1388	=
B-iv-bin-percent	1389	1391	69
I-iv-bin-percent	1391	1392	%
O	1392	1393	)
O	1394	1402	compared
O	1403	1407	with
O	1408	1417	goserelin
O	1418	1423	alone
O	1424	1425	(
O	1425	1427	12
O	1427	1428	-
O	1428	1432	year
O	1433	1436	DFS
O	1437	1438	=
B-cv-bin-percent	1439	1441	61
I-cv-bin-percent	1441	1442	%
O	1442	1443	,
O	1444	1445	P
O	1445	1446	=
O	1447	1449	NS
O	1449	1450	)
O	1450	1451	.

O	1452	1455	For
O	1456	1459	pre
O	1459	1460	/
O	1460	1474	perimenopausal
O	1475	1480	women
O	1481	1485	with
O	1486	1491	lymph
O	1491	1492	-
O	1492	1496	node
O	1496	1497	-
O	1497	1505	negative
O	1506	1508	ER
O	1508	1509	-
O	1509	1517	positive
O	1518	1524	breast
O	1525	1531	cancer
O	1531	1532	,
O	1533	1536	CMF
O	1537	1545	followed
O	1546	1548	by
O	1549	1558	goserelin
O	1559	1567	improved
O	1568	1571	DFS
O	1572	1574	in
O	1575	1585	comparison
O	1586	1590	with
O	1591	1597	either
O	1598	1606	modality
O	1607	1612	alone
O	1612	1613	.

O	1614	1617	The
O	1618	1629	improvement
O	1630	1633	was
O	1634	1637	the
O	1638	1642	most
O	1643	1653	pronounced
O	1654	1656	in
O	1657	1662	those
O	1663	1667	aged
O	1668	1673	below
O	1674	1676	40
O	1676	1677	,
O	1678	1688	suggesting
O	1689	1691	an
O	1692	1701	endocrine
O	1702	1708	effect
O	1709	1711	of
O	1712	1721	prolonged
O	1722	1725	CMF
O	1725	1726	-
O	1726	1733	induced
O	1734	1744	amenorrhea
O	1744	1745	.
